Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $30.0909.

Several equities analysts have commented on IMNM shares. Stephens increased their price objective on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Leerink Partners set a $40.00 target price on Immunome in a report on Monday, December 15th. Finally, The Goldman Sachs Group assumed coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price on the stock.

Immunome Price Performance

NASDAQ IMNM opened at $20.82 on Monday. Immunome has a 1-year low of $5.15 and a 1-year high of $25.30. The business has a 50 day simple moving average of $18.86 and a two-hundred day simple moving average of $13.60. The stock has a market capitalization of $1.91 billion, a PE ratio of -7.06 and a beta of 2.22.

Immunome (NASDAQ:IMNM) last posted its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, analysts anticipate that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares in the company, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall acquired 46,511 shares of Immunome stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $21.50 per share, for a total transaction of $999,986.50. Following the completion of the transaction, the chief executive officer directly owned 853,247 shares in the company, valued at $18,344,810.50. This trade represents a 5.77% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 68,518 shares of company stock worth $1,453,958 over the last quarter. Insiders own 7.69% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Stoneridge Investment Partners LLC grew its position in shares of Immunome by 5.4% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Immunome by 6.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after acquiring an additional 631 shares in the last quarter. Creative Planning increased its position in Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Immunome by 6.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after purchasing an additional 1,188 shares in the last quarter. Finally, Main Management ETF Advisors LLC lifted its position in shares of Immunome by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock worth $716,000 after purchasing an additional 1,248 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.